Bristol Myers Squibb is withdrawing the biopharmaceutical giant’s Istodax from the market after recent trials showed that the peripheral T-cell lymphoma drug did not achieve primary efficacy endpoint.
Bristol Myers Squibb Co. reported second-quarter 2021 earnings that topped Wall Street estimates, as sales of the company’s flagship cancer treatment Opdivo returned to growth after missing estimates in the previous quarter.
California-based biopharmaceutical firm BridgeBio Pharma announced a funding collaboration with Bristol Myers Squibb to evaluate a potential treatment for patients with difficult-to-treat cancers.
Bristol Myers Squibb shared new details on the global biopharmaceutical firm’s Phase III research on a potential first-line treatment for people who have been diagnosed with recurrent or metastatic squamous cell carcinoma of the head and neck.
Bristol Myers Squibb and Eisai forged a strategic collaboration that could be worth nearly $2.5 billion to jointly develop MORAb-202, an antibody drug conjugate (ADC) to be used against certain solid tumors across several different cancer types.
Med Ad News talked to Wendbush Securities analysts David Nierengarten, Laura Chico, and Liana Moussatos about various new drug approvals and other recent news updates in the industry.
As the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting presents many clinical trial updates, there appears to be a theme: access to drugs and pricing.
Bristol Myers Squibb Co. was sued for $6.4 billion on June 3 for allegedly delaying the company’s Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp., which the drugmaker bought in 2019.
The U.S. Food and Drug Administration approved Bristol Myers Squibb’s oral drug Zeposia to treat adults with ulcerative colitis, a chronic inflammatory bowel disease.
The U.S. Food and Drug Administration approved Bristol Myers Squibb’s Opdivo (nivolumab, injection for intravenous use) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT).
